By Neha MathurJun 29 2023Reviewed by Lily Ramsey, LLM In a recent study published in The Lancet, researchers performed a phase III randomized clinical trial in nine countries across North America, Asia, and Europe to assess the effectiveness of semaglutide as the oral treatment of obesity in adults without type 2 diabetes .
It is given orally once daily at 7 mg and 14 mg doses for the treatment of T2D to improve glycaemic control and concurrently reduce body weight. Note that obesity treatment is key to the management of several obesity-related comorbidities. Next, the researchers evaluated two outcomes in parallel, i.e., coprimary endpoints. First, they determined the percentage change in body weight of all participants at week 68, even if they discontinued treatment or used other bodyweight-lowering therapies.
As confirmatory secondary endpoints, the team assessed whether participants attained at least 10%, 15%, and 20% bodyweight reduction till week 68 and reported any physical function outcomes, which included absolute body weight, BMI, waist circumference, blood pressure, glucose homeostasis changes, and glycaemic status.
The average body weight change from baseline to week 68 was 15·1% with oral semaglutide 50 mg vs. –2·4% with placebo. Most participants completed treatment by week 68, and 94% attended the end-of-trial visit at week 75, irrespective of treatment completion.
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NewsMedical - 🏆 19. / 71 Read more »